Evolva Holding SA (EVE.SW) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

EVE.SW · Stock Price

CHF 0.96-0.14 (-12.73%)

Market Cap: $9.0M

Historical price data

Market Cap: $9.0MPipeline: 1 drugFounded: 2004HQ: Reinach, Switzerland

Sector Ranking#13 in Synthetic Biology

Overview

EvoNext Holdings SA represents the corporate remnant of Evolva Holding SA, a once-prominent Swiss synthetic biology company founded in 2004. Evolva's original mission was to engineer yeast strains via precision fermentation to produce sustainable, high-value ingredients for health, nutrition, and flavors. After years of development and commercialization of products like resveratrol, the company faced severe financial distress, leading to the 2023 sale of its operating assets to Danstar Ferment AG (Lallemand Inc.) and subsequent delisting. EvoNext's current strategy is limited to managing the remaining corporate entity and any potential future earn-out payments from the asset sale.

Biotech

Technology Platform

Historically based on synthetic biology and precision fermentation to engineer yeast strains for the production of high-value ingredients. The platform is no longer active following the sale of all operating assets.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
EV-077 + Placebo	Type 2 Diabetes	Phase 2

Opportunities

The sole opportunity for residual shareholder value is the remote possibility that the sold business, now under Danstar Ferment AG, meets future sales targets and triggers an earn-out payment to EvoNext Holdings SA.

Risk Factors

EvoNext is a non-operating corporate shell with no business, revenue, or pipeline.

The contingent earn-out payments are unlikely to materialize based on recent performance.

Shareholders face illiquidity and minimal prospects for capital return.

Competitive Landscape

As a holding company with no operations, EvoNext has no competitive position. Its predecessor, Evolva, historically competed with synthetic biology firms like Amyris and Ginkgo, and ingredient suppliers like Givaudan and IFF.